CN Patent

CN109890808A — 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物

Assigned to Gilead Sciences Inc · Expires 2019-06-14 · 7y expired

What this patent protects

本发明涉及式(Ia)、(Ib)、(IIa)和(IIb)的化合物，式(Ia)、(Ib)、(IIa)和(IIb)的化合物可用于治疗逆转录病毒病毒感染，包括由HIV引起的感染。

USPTO Abstract

本发明涉及式(Ia)、(Ib)、(IIa)和(IIb)的化合物，式(Ia)、(Ib)、(IIa)和(IIb)的化合物可用于治疗逆转录病毒病毒感染，包括由HIV引起的感染。

Drugs covered by this patent

lenacapavir-sodium (LENACAPAVIR SODIUM)

Patent Metadata

Patent number: CN109890808A
Jurisdiction: CN
Classification: —
Expires: 2019-06-14
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.